| Literature DB >> 27517054 |
Xue Zhao1, Xiaokun Gang1, Yujia Liu1, Chenglin Sun1, Qing Han2, Guixia Wang1.
Abstract
A growing body of evidence has shown the intimate relationship between metabolomic profiles and insulin resistance (IR) in obese adults, while little is known about childhood obesity. In this review, we searched available papers addressing metabolomic profiles and IR in obese children from inception to February 2016 on MEDLINE, Web of Science, the Cochrane Library, ClinicalTrials.gov, and EMASE. HOMA-IR was applied as surrogate markers of IR and related metabolic disorders at both baseline and follow-up. To minimize selection bias, two investigators independently completed this work. After critical selection, 10 studies (including 2,673 participants) were eligible and evaluated by using QUADOMICS for quality assessment. Six of the 10 studies were classified as "high quality." Then we generated all the metabolites identified in each study and found amino acid metabolism and lipid metabolism were the main affected metabolic pathways in obese children. Among identified metabolites, branched-chain amino acids (BCAAs), aromatic amino acids (AAAs), and acylcarnitines were reported to be associated with IR as biomarkers most frequently. Additionally, BCAAs and tyrosine seemed to be relevant to future metabolic risk in the long-term follow-up cohorts, emphasizing the importance of early diagnosis and prevention strategy. Because of limited scale and design heterogeneity of existing studies, future studies might focus on validating above findings in more large-scale and longitudinal studies with elaborate design.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27517054 PMCID: PMC4969529 DOI: 10.1155/2016/8160545
Source DB: PubMed Journal: J Diabetes Res Impact factor: 4.011
Figure 1The flowchart of literature selection in this review.
Characteristics of study population, HOMA-IR, and identified metabolomic profiles in 10 included studies.
| Study | Year | Num | Male | Type | Mean age | BMI | HOMA-IR | Plasma metabolomic profiles identified |
|---|---|---|---|---|---|---|---|---|
| Hellmuth et al. [ | 2016 | 80 | 45% | C | 11.5 ± 2.4 | Obese: | Obese: | Total aromatic amino acids, C0, C3, C6:1-DC, C6-oxo, C4/C5-oxo, C5/C6-oxo, C6:1-DC/C5:1, C6-oxo/xLeu, valine, tyrosine, proline, serine, phenylalanine, glycine, histidine, and methionine |
|
| ||||||||
| Butte et al. [ | 2015 | 803 | 50% | O | 11.1 ± 3.9 | Obese: | Obese: | Leucine, isoleucine, valine, glutamate, alanine, aspartate, glycine, serine, threonine, histidine, PUFA, peptide, tyrosine, methionine, bradykinin, lysine, phenylalanine, pyroglutamine, polyamine, urea cycle, polypeptide, short-chain acylcarnitines, long-chain acylcarnitine, ketone bodies, dicarboxylated fatty acids, lysolipid, medium-chain fatty acid, monoacylglycerol, phospholipid, androsterone sulfate, epiandrosterone sulfate, steroid derivatives, mannose, pyruvate, glycerate, pantothenate and CoA, citrate, purine, xanthine, pyrimidine, 2-methylbutyrylcarnitine, 3-methyl-2-oxobutyrate, and isovalerylcarnitine |
|
| ||||||||
| Lee et al. [ | 2015 | 109 | 100% | C | 10.4 ± 0.6 | Obese: | Obese | Leucine, isoleucine, valine, phenylalanine, tyrosine, glutamine, alanine, glycine, serine, asparagine, lysine, glutamate, proline, citrulline, alpha-aminoadipic acid, C0, C3, C5, C7-DC, C16, and C18 |
|
| ||||||||
| Perng et al. [ | 2014 | 262 | 50% | O | 8.0 ± 0.9 | Obese: | Obese: | Leucine, isoleucine, valine, phenylalanine, C3, C5, tryptophan, 3-methyl-2-oxovalerate, kynurenine, tyrosine, |
|
| ||||||||
| Newbern et al. [ | 2014 | 82 | 50% | O | 13.8 ± 0.2 | Obese male: | Obese male: | Valine, leucine/isoleucine, glutamate/glutamine, C2, C3, C5, total BCAA, |
|
| ||||||||
| Farook et al. [ | 2015 | 42 | 45% | O | 11.5 ± 3.1 | BMI, | Obese: | L-Thyronine, bradykinin, indole-3-propionic acid, naringenin, 2-methylbutyroylcarnitine, 3-hydroxyquinine, LysoPC (18:1), vitamin D3, calicoferol B, diglyceride, malvidin 3-(6-acetyl glucoside), linoleic acid, phosphatidylethanolamine, and phosphocholine (16:1) |
|
| ||||||||
| Mccormack et al. [ | 2013 | 69 | 58% | C | 13.3 ± 2.9 | 1.04 ± 1.23 | 1.84 ± 2.04 | Valine, leucine, isoleucine, citrulline, glutamate, 3-hydroxyanthranilic acid, and phenylalanine |
|
| ||||||||
| Michaliszyn et al. [ | 2012 | 139 | 47% | O | 13.4 ± 0.2 | BMI, | Obese: | Valine, leucine/isoleucine, methionine, phenylalanine, glycine, serine, histidine, arginine, C2, C3, C5, C4, tyrosine, alanine, and citrulline |
|
| ||||||||
| Mihalik et al. [ | 2012 | 103 | 52% | O | 13.3 ± 0.2 | BMI, obese: | Obese: | Leucine/isoleucine, valine, phenylalanine, methionine, glycine, serine, histidine, arginine, alanine, citrulline, C2, C3, C4, C4-OH, C5, C5:1, C5-OH, C6, C6-OH, C8, C8:1, C10, C10:1, C10:2, C12, C12-OH, C12:1, C14, C14:1, C14:2, C16, C16:1, C16-OH, C18, C18:1, C18:1-OH-CN, C18:2, and free CN |
|
| ||||||||
| Elshorbagy et al. [ | 2012 | 984 | 50% | O | 11.0 ± 2.2 | BMI, obese: | Obese: | Total homocysteine, total cysteine, total glutathione, nonesterified fatty acids, and methionine |
Note: num: number; O: observational study; C: cohort study; BMIz: body mass index z score; HOMA-IR: homeostasis model assessment of insulin resistance; C0: C0 acylcarnitine; C2: C2 acylcarnitine; C3: C3 acylcarnitine; C4: C4 acylcarnitine; C5: C5 acylcarnitine; C7: C7 acylcarnitine; C16: C16 acylcarnitine; C18: C18 acylcarnitine; PUFA: polyunsaturated fatty acids.
Specific metabolites identified to be related to insulin resistance and future metabolic risk based on 10 included studies.
| Affected metabolic pathways | Metabolites related to IR | Reference | |
|---|---|---|---|
| Amino acids metabolism | Branched-chain amino acids | Valine, leucine, and isoleucine | [ |
| Isovalerylcarnitine and isobutyrylcarnitine | [ | ||
| Aromatic amino acids | Tyrosine and phenylalanine | [ | |
| Sulfur amino acids | Cysteine and homocysteine | [ | |
| Other | Asparagine, glycine, serine, proline, citrulline, glutamate, and methionine | [ | |
|
| |||
| Lipid metabolism | Acylcarnitines | C2, C3, C5, C2/(C3 + C5), C5/C6-oxo, C4/C5-oxo, C6-oxo/xLeu, and long-chain dicarboxylic acylcarnitines | [ |
| Fatty acids | NEFA and FAO by-products | [ | |
| Steroid | Androgen hormones | [ | |